PROCEPT BioRobotics (PRCT) Financials

$58.53 +1.15 (+2.00%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$58.98 +0.45 (+0.76%)

As of 05/27/2025 07:29 PM Eastern

Annual Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Income / (Loss) Attributable to Common Shareholders	-91	-106	-87	-60	-53
Consolidated Net Income / (Loss)	-91	-106	-87	-60	-53
Net Income / (Loss) Continuing Operations	-91	-106	-87	-60	-53
Total Pre-Tax Income	-91	-106	-87	-60	-53
Total Operating Income	-97	-109	-81	-54	-48
Total Gross Profit	137	71	37	16	-1.26
Total Revenue	224	136	75	34	7.72
Operating Revenue	224	136	75	34	-
Total Cost of Revenue	87	65	38	19	8.97
Operating Cost of Revenue	87	65	38	19	8.97
Total Operating Expenses	234	180	118	70	47
Selling, General & Admin Expense	171	132	89	51	30
Research & Development Expense	62	48	29	19	16
Total Other Income / (Expense), net	5.20	3.27	-6.43	-5.69	-5.22
Interest Expense	4.18	4.00	8.44	5.81	5.26
Other Income / (Expense), net	9.39	7.27	2.01	0.12	0.04
Basic Earnings per Share	($1.75)	($2.24)	($1.96)	($3.63)	($14.47)
Weighted Average Basic Shares Outstanding	52.13M	47.26M	44.40M	16.48M	3.66M
Diluted Earnings per Share	($1.75)	($2.24)	($1.96)	($3.63)	($14.47)
Weighted Average Diluted Shares Outstanding	52.13M	47.26M	44.40M	16.48M	3.66M
Weighted Average Basic & Diluted Shares Outstanding	54.82M	50.96M	44.87M	43.99M	-

This table shows PROCEPT BioRobotics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Consolidated Net Income / (Loss)	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Net Income / (Loss) Continuing Operations	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Total Pre-Tax Income	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Total Operating Income	-27	-20	-22	-27	-28	-30	-26	-26	-28	-25	-22
Total Gross Profit	44	44	37	31	25	21	19	18	12	11	10
Total Revenue	69	68	58	53	45	44	35	33	24	24	20
Operating Revenue	69	68	58	53	45	44	35	33	24	24	20
Total Cost of Revenue	25	25	21	22	20	22	16	15	12	13	10
Operating Cost of Revenue	25	25	21	22	20	22	16	15	12	13	10
Total Operating Expenses	72	63	59	58	53	51	44	44	41	36	32
Selling, General & Admin Expense	55	48	43	41	40	36	33	32	30	26	25
Research & Development Expense	16	15	17	18	13	14	12	12	11	9.68	7.58
Total Other Income / (Expense), net	2.70	0.85	1.45	1.20	1.69	2.05	0.99	0.34	-0.11	-3.13	-0.51
Interest Expense	0.88	0.97	1.14	1.03	1.05	1.13	1.02	0.97	0.89	4.12	1.46
Other Income / (Expense), net	3.58	1.82	2.59	2.23	2.74	3.18	2.01	1.31	0.78	0.99	0.95
Basic Earnings per Share	($0.45)	($0.34)	($0.40)	($0.50)	($0.51)	($0.54)	($0.51)	($0.56)	($0.63)	($0.63)	($0.51)
Weighted Average Basic Shares Outstanding	54.92M	52.13M	52.01M	51.62M	51.01M	47.26M	48.31M	45.16M	45.07M	44.40M	44.64M
Diluted Earnings per Share	($0.45)	($0.34)	($0.40)	($0.50)	($0.51)	($0.54)	($0.51)	($0.56)	($0.63)	($0.63)	($0.51)
Weighted Average Diluted Shares Outstanding	54.92M	52.13M	52.01M	51.62M	51.01M	47.26M	48.31M	45.16M	45.07M	44.40M	44.64M
Weighted Average Basic & Diluted Shares Outstanding	55.33M	54.82M	52.18M	51.93M	51.42M	50.96M	50.50M	45.28M	45.05M	44.87M	44.72M

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Net Change in Cash & Equivalents	77	35	-79	204	58
Net Cash From Operating Activities	-99	-108	-80	-57	-48
Net Cash From Continuing Operating Activities	-99	-108	-80	-57	-48
Net Income / (Loss) Continuing Operations	-91	-106	-87	-60	-53
Consolidated Net Income / (Loss)	-91	-106	-87	-60	-53
Depreciation Expense	5.23	3.81	2.84	-	2.86
Non-Cash Adjustments To Reconcile Net Income	34	25	15	3.90	2.30
Changes in Operating Assets and Liabilities, net	-47	-31	-11	-4.71	-0.48
Net Cash From Investing Activities	-4.41	-25	-2.65	-0.59	-0.23
Net Cash From Continuing Investing Activities	-4.41	-25	-2.65	-0.59	-0.23
Purchase of Property, Plant & Equipment	-4.41	-25	-2.65	-0.59	-0.23
Net Cash From Financing Activities	180	168	3.61	262	107
Net Cash From Continuing Financing Activities	180	168	3.61	262	107
Repayment of Debt	0.00	0.00	-51	0.00	-
Issuance of Debt	4.53	3.61	54	0.00	25
Issuance of Common Equity	165	162	0.00	172	0.00
Other Financing Activities, net	11	2.48	1.01	5.04	5.60
Cash Interest Paid	3.97	4.06	4.29	4.75	3.97

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-18	137	-17	-11	-32	-31	137	-31	-41	-27	-21
Net Cash From Operating Activities	-17	-32	-19	-16	-32	-25	-19	-28	-36	-25	-20
Net Cash From Continuing Operating Activities	-17	-32	-19	-16	-32	-25	-19	-28	-36	-25	-20
Net Income / (Loss) Continuing Operations	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Consolidated Net Income / (Loss)	-25	-19	-21	-26	-26	-28	-25	-25	-28	-28	-23
Depreciation Expense	1.48	1.45	1.33	1.27	1.18	1.32	1.05	0.64	0.79	0.66	0.70
Non-Cash Adjustments To Reconcile Net Income	11	7.38	9.25	8.80	8.76	4.87	5.72	6.88	7.66	6.95	4.15
Changes in Operating Assets and Liabilities, net	-4.33	-22	-8.40	-0.18	-16	-3.48	-1.09	-11	-16	-4.62	-2.09
Net Cash From Investing Activities	-1.84	-1.17	-0.25	-1.04	-1.95	-8.72	-5.78	-5.37	-5.34	-0.87	-1.51
Net Cash From Continuing Investing Activities	-1.84	-1.17	-0.25	-1.04	-1.95	-8.72	-5.78	-5.37	-5.34	-0.87	-1.51
Purchase of Property, Plant & Equipment	-1.84	-1.17	-0.25	-1.04	-1.95	-8.72	-5.78	-5.37	-5.34	-0.87	-1.51
Net Cash From Financing Activities	1.30	171	1.72	5.30	2.59	2.87	162	2.43	0.38	-1.32	0.78
Net Cash From Continuing Financing Activities	1.30	171	1.72	5.30	2.59	2.87	162	2.43	0.38	-1.32	0.78
Other Financing Activities, net	1.30	3.60	1.72	3.17	2.59	0.97	0.41	0.71	0.38	-2.63	0.78
Cash Interest Paid	0.89	0.92	1.01	1.03	1.00	1.00	0.99	0.94	1.12	0.72	1.20

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	534	405	309	337	126
Total Current Assets	482	351	273	326	110
Cash & Equivalents	334	257	222	304	100
Accounts Receivable	83	48	15	4.46	1.55
Inventories, net	56	40	29	13	6.92
Prepaid Expenses	8.45	5.21	6.18	4.24	1.65
Plant, Property, & Equipment, net	27	29	8.66	5.05	8.27
Total Noncurrent Assets	25	25	28	5.81	7.44
Goodwill	0.93	1.20	1.48	1.75	2.02
Other Noncurrent Operating Assets	25	24	27	4.06	5.42
Total Liabilities & Shareholders' Equity	534	405	309	337	126
Total Liabilities	132	124	112	70	65
Total Current Liabilities	53	46	35	16	15
Accounts Payable	10	13	9.39	2.03	1.24
Accrued Expenses	22	17	13	6.48	4.64
Current Deferred Revenue	9.57	5.66	2.86	1.03	0.23
Other Current Liabilities	12	9.89	9.60	6.71	3.86
Total Noncurrent Liabilities	79	78	77	54	50
Long-Term Debt	51	51	51	50	44
Other Noncurrent Operating Liabilities	27	27	26	3.69	6.08
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	402	281	197	267	-183
Total Preferred & Common Equity	402	281	197	267	-183
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	402	281	197	267	-183
Common Stock	948	735	546	529	19
Retained Earnings	-546	-455	-349	-262	-202
Accumulated Other Comprehensive Income / (Loss)	0.11	0.08	-0.01	-0.05	-0.01

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	519	374	374	383	421	272	284	324
Total Current Assets	466	323	322	329	369	230	246	289
Cash & Equivalents	316	197	214	226	287	150	181	249
Accounts Receivable	79	69	59	56	35	33	21	13
Inventories, net	62	51	44	42	42	43	39	22
Prepaid Expenses	7.99	6.32	5.02	5.91	3.98	3.74	4.26	4.52
Plant, Property, & Equipment, net	28	27	28	28	27	16	12	5.12
Total Noncurrent Assets	25	25	25	25	25	26	27	30
Goodwill	0.86	1.00	1.07	1.14	1.27	1.34	1.41	1.55
Other Noncurrent Operating Assets	25	24	24	24	24	25	26	28
Total Liabilities & Shareholders' Equity	519	374	374	383	421	272	284	324
Total Liabilities	130	133	123	119	122	117	111	103
Total Current Liabilities	52	54	43	39	41	36	33	27
Short-Term Debt	1.98	-	-	1.70	-	-	3.00	2.47
Accounts Payable	15	15	9.95	10	14	10	10	6.33
Accrued Expenses	15	19	15	11	13	9.95	7.41	10
Current Deferred Revenue	9.80	7.99	6.55	5.86	5.01	4.72	3.94	2.34
Other Current Liabilities	10	12	11	9.54	9.49	11	7.81	5.93
Total Noncurrent Liabilities	78	79	80	80	80	81	79	76
Long-Term Debt	51	51	51	51	51	51	51	51
Other Noncurrent Operating Liabilities	27	28	28	29	29	29	28	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	389	241	252	264	299	156	173	221
Total Preferred & Common Equity	389	241	252	264	299	156	173	221
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	389	241	252	264	299	156	173	221
Common Stock	960	768	758	744	726	558	550	541
Retained Earnings	-571	-527	-506	-481	-427	-402	-377	-321
Accumulated Other Comprehensive Income / (Loss)	0.22	-0.02	-0.00	0.11	-0.01	-0.01	0.02	0.22

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Growth Metrics	-	-	-	-	-
Revenue Growth	64.84%	81.55%	117.60%	346.72%	0.00%
EBITDA Growth	16.41%	-29.29%	-49.59%	-12.96%	0.00%
EBIT Growth	14.40%	-29.46%	-45.65%	-13.16%	0.00%
NOPAT Growth	11.50%	-35.24%	-49.04%	-13.31%	0.00%
Net Income Growth	13.68%	-21.51%	-45.61%	-12.89%	0.00%
EPS Growth	21.88%	-14.29%	46.01%	74.91%	0.00%
Operating Cash Flow Growth	8.14%	-34.36%	-40.20%	-18.60%	0.00%
Free Cash Flow Firm Growth	10.28%	-81.09%	-69.63%	0.00%	0.00%
Invested Capital Growth	60.24%	191.90%	100.78%	30.52%	0.00%
Revenue Q/Q Growth	12.34%	17.02%	22.22%	0.00%	0.00%
EBITDA Q/Q Growth	14.34%	1.48%	-6.01%	0.00%	0.00%
EBIT Q/Q Growth	8.87%	-2.34%	-9.98%	0.00%	0.00%
NOPAT Q/Q Growth	9.25%	-4.32%	-11.32%	0.00%	0.00%
Net Income Q/Q Growth	8.64%	0.63%	-12.70%	0.00%	0.00%
EPS Q/Q Growth	10.26%	3.86%	-229.80%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-8.29%	0.35%	-12.13%	-5.58%	0.00%
Free Cash Flow Firm Q/Q Growth	-4.75%	-12.84%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	25.10%	19.22%	3.80%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	61.07%	52.17%	49.44%	46.02%	-16.26%
EBITDA Margin	-36.52%	-72.03%	-101.14%	-147.13%	-581.81%
Operating Margin	-43.04%	-80.16%	-107.61%	-157.12%	-619.44%
EBIT Margin	-38.86%	-74.82%	-104.93%	-156.77%	-618.87%
Profit (Net Income) Margin	-40.72%	-77.76%	-116.18%	-173.62%	-687.04%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	104.80%	103.92%	110.72%	110.75%	111.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-69.42%	-152.05%	-294.12%	-336.08%	-341.86%
ROIC Less NNEP Spread (ROIC-NNEP)	-59.68%	-136.42%	-279.73%	-321.72%	-303.64%
Return on Net Nonoperating Assets (RNNOA)	42.65%	107.73%	256.57%	299.59%	254.89%
Return on Equity (ROE)	-26.77%	-44.32%	-37.55%	-36.49%	-86.97%
Cash Return on Invested Capital (CROIC)	-115.72%	-249.98%	-361.13%	-362.56%	0.00%
Operating Return on Assets (OROA)	-18.58%	-28.54%	-24.36%	-23.35%	-37.91%
Return on Assets (ROA)	-19.48%	-29.66%	-26.97%	-25.85%	-42.09%
Return on Common Equity (ROCE)	-26.77%	-44.32%	-37.55%	-9.37%	260.94%
Return on Equity Simple (ROE_SIMPLE)	-22.73%	-37.72%	-44.22%	-22.41%	28.99%
Net Operating Profit after Tax (NOPAT)	-68	-76	-57	-38	-33
NOPAT Margin	-30.12%	-56.11%	-75.33%	-109.98%	-433.61%
Net Nonoperating Expense Percent (NNEP)	-9.74%	-15.63%	-14.40%	-14.36%	-38.22%
Return On Investment Capital (ROIC_SIMPLE)	-14.91%	-23.01%	-22.76%	-	-
Cost of Revenue to Revenue	38.93%	47.83%	50.56%	53.98%	116.26%
SG&A Expenses to Revenue	76.35%	96.76%	118.42%	148.05%	392.28%
R&D to Revenue	27.75%	35.57%	38.63%	55.10%	210.90%
Operating Expenses to Revenue	104.10%	132.33%	157.05%	203.14%	603.17%
Earnings before Interest and Taxes (EBIT)	-87	-102	-79	-54	-48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-82	-98	-76	-51	-45
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	10.45	7.54	9.43	4.07	0.00
Price to Tangible Book Value (P/TBV)	10.47	7.57	9.50	4.10	0.00
Price to Revenue (P/Rev)	18.72	15.54	24.76	31.56	17.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	32.67	25.52	65.74	65.25	33.73
Enterprise Value to Revenue (EV/Rev)	17.46	14.03	22.48	24.18	42.79
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.13	0.18	0.26	0.19	0.80
Long-Term Debt to Equity	0.13	0.18	0.26	0.19	0.73
Financial Leverage	-0.71	-0.79	-0.92	-0.93	-0.84
Leverage Ratio	1.37	1.49	1.39	1.41	2.07
Compound Leverage Factor	1.44	1.55	1.54	1.56	2.29
Debt to Total Capital	11.35%	15.46%	20.63%	15.77%	44.54%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	4.14%
Long-Term Debt to Total Capital	11.35%	15.46%	20.63%	15.77%	40.40%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	221.85%
Common Equity to Total Capital	88.65%	84.54%	79.37%	84.23%	-166.39%
Debt to EBITDA	-0.63	-0.52	-0.68	-0.99	-1.09
Net Debt to EBITDA	3.44	2.10	2.26	5.01	1.14
Long-Term Debt to EBITDA	-0.63	-0.52	-0.68	-0.99	-0.99
Debt to NOPAT	-0.76	-0.67	-0.91	-1.32	-1.46
Net Debt to NOPAT	4.17	2.69	3.03	6.71	1.53
Long-Term Debt to NOPAT	-0.76	-0.67	-0.91	-1.32	-1.33
Altman Z-Score	18.54	9.08	8.67	8.92	-1.25
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	74.33%	400.02%
Liquidity Ratios	-	-	-	-	-
Current Ratio	9.07	7.63	7.73	20.08	7.59
Quick Ratio	7.85	6.65	6.72	19.01	7.00
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-113	-126	-69	-41	0.00
Operating Cash Flow to CapEx	-2,250.24%	-428.48%	-3,029.85%	-9,684.80%	-20,748.07%
Free Cash Flow to Firm to Interest Expense	-26.94	-31.45	-8.22	-7.04	0.00
Operating Cash Flow to Interest Expense	-23.71	-27.03	-9.52	-9.87	-9.19
Operating Cash Flow Less CapEx to Interest Expense	-24.77	-33.34	-9.84	-9.97	-9.23
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.48	0.38	0.23	0.15	0.06
Accounts Receivable Turnover	3.40	4.28	7.60	11.47	4.98
Inventory Turnover	1.82	1.91	1.82	1.85	1.30
Fixed Asset Turnover	8.10	7.28	10.95	5.18	0.93
Accounts Payable Turnover	7.43	5.69	6.64	11.38	7.24
Days Sales Outstanding (DSO)	107.20	85.29	48.02	31.83	73.26
Days Inventory Outstanding (DIO)	200.30	191.34	200.60	196.85	281.68
Days Payable Outstanding (DPO)	49.14	64.13	54.95	32.06	50.45
Cash Conversion Cycle (CCC)	258.37	212.51	193.66	196.62	304.50
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	120	75	26	13	9.79
Invested Capital Turnover	2.30	2.71	3.90	3.06	0.79
Increase / (Decrease) in Invested Capital	45	49	13	2.99	0.00
Enterprise Value (EV)	3,920	1,911	1,686	834	330
Market Capitalization	4,202	2,116	1,858	1,088	138
Book Value per Share	$7.71	$5.56	$4.41	$6.14	($49.93)
Tangible Book Value per Share	$7.69	$5.54	$4.37	$6.10	($50.48)
Total Capital	454	332	248	317	110
Total Debt	51	51	51	50	49
Total Long-Term Debt	51	51	51	50	44
Net Debt	-282	-206	-171	-254	-51
Capital Expenditures (CapEx)	4.41	25	2.65	0.59	0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	95	47	15	5.61	0.15
Debt-free Net Working Capital (DFNWC)	429	305	237	310	100
Net Working Capital (NWC)	429	305	237	310	96
Net Nonoperating Expense (NNE)	24	29	31	22	20
Net Nonoperating Obligations (NNO)	-282	-206	-171	-254	-51
Total Depreciation and Amortization (D&A)	5.23	3.81	2.84	3.32	2.86
Debt-free, Cash-free Net Working Capital to Revenue	42.31%	34.82%	19.60%	16.28%	1.96%
Debt-free Net Working Capital to Revenue	190.96%	223.69%	316.39%	899.05%	1,299.48%
Net Working Capital to Revenue	190.96%	223.69%	316.39%	899.05%	1,240.51%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.75)	($2.24)	($1.96)	($3.63)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	52.13M	47.26M	44.40M	16.48M	0.00
Adjusted Diluted Earnings per Share	($1.75)	($2.24)	($1.96)	($3.63)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	52.13M	47.26M	44.40M	16.48M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.82M	50.96M	44.87M	43.99M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-68	-76	-57	-38	-33
Normalized NOPAT Margin	-30.12%	-56.11%	-75.33%	-109.98%	-433.61%
Pre Tax Income Margin	-40.72%	-77.76%	-116.18%	-173.62%	-687.04%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-20.85	-25.51	-9.33	-9.30	-9.08
NOPAT to Interest Expense	-16.16	-19.13	-6.69	-6.53	-6.36
EBIT Less CapEx to Interest Expense	-21.90	-31.82	-9.64	-9.40	-9.12
NOPAT Less CapEx to Interest Expense	-17.22	-25.44	-7.01	-6.63	-6.40
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	55.28%	56.57%	66.29%	61.17%	82.51%	83.29%	72.50%	98.33%	71.90%	134.56%	134.76%
EBITDA Growth	5.66%	34.43%	17.93%	1.48%	11.48%	-7.18%	-10.24%	-39.07%	-78.63%	-38.32%	-72.79%
EBIT Growth	4.22%	32.20%	15.97%	-1.13%	9.73%	-9.70%	-11.56%	-37.07%	-75.07%	-42.24%	-67.47%
NOPAT Growth	0.76%	33.32%	12.43%	-4.69%	2.57%	-18.05%	-15.85%	-43.36%	-80.70%	-48.77%	-72.74%
Net Income Growth	4.70%	31.45%	14.82%	-1.35%	8.87%	2.36%	-8.88%	-31.80%	-65.75%	-53.54%	-60.34%
EPS Growth	11.76%	37.04%	21.57%	10.71%	19.05%	14.29%	0.00%	-30.23%	-61.54%	-122.18%	58.20%
Operating Cash Flow Growth	47.41%	-30.65%	0.75%	44.47%	10.14%	1.51%	4.57%	-65.47%	-97.07%	-52.79%	-55.68%
Free Cash Flow Firm Growth	17.14%	15.76%	12.89%	2.55%	-39.60%	-129.96%	-103.00%	-51.47%	-57.41%	0.00%	-28.06%
Invested Capital Growth	38.11%	60.24%	52.70%	57.10%	100.68%	191.90%	154.14%	156.06%	143.73%	100.78%	96.27%
Revenue Q/Q Growth	1.36%	16.90%	9.40%	19.79%	2.20%	24.16%	6.04%	35.65%	2.64%	16.85%	21.92%
EBITDA Q/Q Growth	-36.21%	11.20%	20.67%	1.69%	10.06%	-11.15%	4.77%	11.67%	-11.46%	-14.32%	-20.14%
EBIT Q/Q Growth	-33.39%	9.82%	19.36%	1.27%	5.57%	-11.77%	2.95%	11.88%	-14.76%	-13.66%	-19.25%
NOPAT Q/Q Growth	-39.21%	12.11%	16.40%	2.97%	6.46%	-15.42%	0.06%	9.70%	-13.33%	-13.28%	-23.66%
Net Income Q/Q Growth	-31.19%	10.10%	18.15%	1.28%	5.63%	-11.71%	2.62%	11.23%	-1.11%	-24.58%	-17.87%
EPS Q/Q Growth	-32.35%	15.00%	20.00%	1.96%	5.56%	-5.88%	8.93%	11.11%	0.00%	-23.53%	-18.60%
Operating Cash Flow Q/Q Growth	47.58%	-72.29%	-19.47%	51.26%	-30.22%	-30.88%	33.16%	21.12%	-42.72%	-26.81%	-15.91%
Free Cash Flow Firm Q/Q Growth	8.15%	-20.70%	4.63%	21.63%	6.62%	-24.81%	-6.70%	-12.27%	-53.82%	-10.18%	20.39%
Invested Capital Q/Q Growth	5.39%	25.10%	7.64%	-2.68%	22.27%	19.22%	10.74%	24.32%	77.85%	3.80%	11.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	63.85%	64.00%	63.24%	59.01%	56.21%	48.77%	53.77%	55.67%	51.18%	44.90%	50.28%
EBITDA Margin	-32.37%	-24.08%	-31.70%	-43.72%	-53.27%	-57.51%	-64.24%	-71.53%	-109.84%	-98.35%	-100.52%
Operating Margin	-39.67%	-28.89%	-38.42%	-50.28%	-62.08%	-67.83%	-72.96%	-77.41%	-116.28%	-105.31%	-108.63%
EBIT Margin	-34.50%	-26.21%	-33.98%	-46.10%	-55.93%	-60.53%	-67.24%	-73.47%	-113.09%	-101.14%	-103.98%
Profit (Net Income) Margin	-35.77%	-27.63%	-35.93%	-48.03%	-58.28%	-63.11%	-70.14%	-76.38%	-116.72%	-118.48%	-111.13%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	103.68%	105.42%	105.75%	104.19%	104.19%	104.26%	104.32%	103.97%	103.21%	117.15%	106.88%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-63.48%	-46.60%	-67.74%	-85.26%	-99.05%	-128.65%	-135.84%	-139.67%	-215.65%	-287.84%	-250.24%
ROIC Less NNEP Spread (ROIC-NNEP)	-60.94%	-44.52%	-64.98%	-80.03%	-94.65%	-125.04%	-132.75%	-135.03%	-210.88%	-282.84%	-247.18%
Return on Net Nonoperating Assets (RNNOA)	40.60%	31.82%	45.90%	51.41%	64.96%	98.74%	110.41%	108.08%	179.03%	259.42%	228.89%
Return on Equity (ROE)	-22.88%	-14.77%	-21.84%	-33.85%	-34.10%	-29.92%	-25.43%	-31.60%	-36.62%	-28.41%	-21.35%
Cash Return on Invested Capital (CROIC)	-93.93%	-115.72%	-135.63%	-149.70%	-177.66%	-249.98%	-254.48%	-267.23%	-286.88%	-361.13%	0.00%
Operating Return on Assets (OROA)	-19.05%	-12.54%	-17.08%	-25.17%	-26.20%	-23.09%	-21.00%	-25.60%	-31.84%	-23.48%	-18.89%
Return on Assets (ROA)	-19.75%	-13.22%	-18.06%	-26.22%	-27.30%	-24.08%	-21.91%	-26.61%	-32.86%	-27.50%	-20.19%
Return on Common Equity (ROCE)	-22.88%	-14.77%	-21.84%	-33.85%	-34.10%	-29.92%	-25.43%	-31.60%	-36.62%	-28.41%	-21.35%
Return on Equity Simple (ROE_SIMPLE)	-23.18%	0.00%	-41.48%	-41.19%	-39.15%	0.00%	-35.60%	-67.06%	-56.87%	0.00%	-35.03%
Net Operating Profit after Tax (NOPAT)	-19	-14	-16	-19	-19	-21	-18	-18	-20	-18	-15
NOPAT Margin	-27.77%	-20.22%	-26.90%	-35.20%	-43.45%	-47.48%	-51.07%	-54.19%	-81.40%	-73.72%	-76.04%
Net Nonoperating Expense Percent (NNEP)	-2.54%	-2.07%	-2.76%	-5.23%	-4.40%	-3.61%	-3.10%	-4.65%	-4.77%	-5.00%	-3.06%
Return On Investment Capital (ROIC_SIMPLE)	-4.34%	-3.04%	-	-	-	-6.23%	-	-	-	-7.06%	-
Cost of Revenue to Revenue	36.15%	36.00%	36.76%	40.99%	43.79%	51.23%	46.23%	44.33%	48.82%	55.10%	49.72%
SG&A Expenses to Revenue	79.81%	70.81%	73.14%	76.49%	88.91%	83.33%	93.68%	98.00%	123.47%	109.49%	121.65%
R&D to Revenue	23.72%	22.08%	28.52%	32.80%	29.38%	33.26%	33.05%	35.08%	44.00%	40.72%	37.26%
Operating Expenses to Revenue	103.52%	92.89%	101.66%	109.29%	118.29%	116.60%	126.73%	133.08%	167.46%	150.21%	158.91%
Earnings before Interest and Taxes (EBIT)	-24	-18	-20	-25	-25	-26	-24	-24	-28	-24	-21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-22	-16	-19	-23	-24	-25	-23	-24	-27	-23	-20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.21	10.45	17.25	12.48	9.45	7.54	4.96	10.21	7.36	9.43	8.37
Price to Tangible Book Value (P/TBV)	8.23	10.47	17.32	12.53	9.49	7.57	4.98	10.30	7.42	9.50	8.43
Price to Revenue (P/Rev)	12.82	18.72	20.82	17.79	15.96	15.54	12.76	15.67	14.95	24.76	30.12
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.18	32.67	41.87	33.44	25.38	25.52	19.89	26.33	25.14	65.74	66.89
Enterprise Value to Revenue (EV/Rev)	11.77	17.46	20.09	16.87	14.86	14.03	10.73	14.69	13.46	22.48	26.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.13	0.21	0.20	0.20	0.18	0.17	0.33	0.31	0.26	0.24
Long-Term Debt to Equity	0.13	0.13	0.21	0.20	0.19	0.18	0.17	0.33	0.30	0.26	0.23
Financial Leverage	-0.67	-0.71	-0.71	-0.64	-0.69	-0.79	-0.83	-0.80	-0.85	-0.92	-0.93
Leverage Ratio	1.38	1.37	1.47	1.59	1.53	1.49	1.43	1.48	1.42	1.39	1.34
Compound Leverage Factor	1.43	1.45	1.56	1.65	1.59	1.56	1.49	1.54	1.47	1.63	1.43
Debt to Total Capital	12.08%	11.35%	17.58%	16.95%	16.74%	15.46%	14.63%	24.75%	23.86%	20.63%	19.41%
Short-Term Debt to Total Capital	0.45%	0.00%	0.00%	0.00%	0.54%	0.00%	0.00%	0.00%	1.32%	0.00%	0.90%
Long-Term Debt to Total Capital	11.63%	11.35%	17.58%	16.95%	16.20%	15.46%	14.63%	24.75%	22.54%	20.63%	18.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.92%	88.65%	82.42%	83.05%	83.26%	84.54%	85.37%	75.25%	76.14%	79.37%	80.59%
Debt to EBITDA	-0.66	-0.63	-0.54	-0.52	-0.53	-0.52	-0.52	-0.53	-0.60	-0.68	-0.74
Net Debt to EBITDA	3.26	3.44	1.52	1.64	1.74	2.10	2.38	1.02	1.41	2.26	2.74
Long-Term Debt to EBITDA	-0.64	-0.63	-0.54	-0.52	-0.52	-0.52	-0.52	-0.53	-0.57	-0.68	-0.71
Debt to NOPAT	-0.79	-0.76	-0.69	-0.67	-0.70	-0.67	-0.70	-0.72	-0.83	-0.91	-1.05
Net Debt to NOPAT	3.89	4.17	1.95	2.12	2.27	2.69	3.23	1.40	1.95	3.03	3.86
Long-Term Debt to NOPAT	-0.76	-0.76	-0.69	-0.67	-0.68	-0.67	-0.70	-0.72	-0.78	-0.91	-1.00
Altman Z-Score	14.46	18.97	18.03	14.63	11.95	9.70	6.92	7.06	5.89	9.26	10.30
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.95	9.07	6.02	7.51	8.52	7.63	8.91	6.40	7.56	7.73	10.56
Quick Ratio	7.60	7.85	4.95	6.37	7.29	6.65	7.78	5.09	6.20	6.72	9.58
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-59	-49	-51	-65	-70	-56	-52	-47	-30	-28
Operating Cash Flow to CapEx	-924.84%	-2,759.03%	-7,642.28%	-1,508.72%	-1,659.10%	-284.49%	-327.73%	-527.53%	-672.94%	-2,906.93%	-1,311.16%
Free Cash Flow to Firm to Interest Expense	-61.68	-60.78	-42.80	-49.67	-62.47	-62.14	-54.97	-54.40	-52.78	-7.37	-18.96
Operating Cash Flow to Interest Expense	-19.36	-33.43	-16.49	-15.28	-30.90	-22.04	-18.59	-29.37	-40.55	-6.10	-13.64
Operating Cash Flow Less CapEx to Interest Expense	-21.46	-34.64	-16.71	-16.29	-32.76	-29.78	-24.26	-34.93	-46.58	-6.31	-14.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.55	0.48	0.50	0.55	0.47	0.38	0.31	0.35	0.28	0.23	0.18
Accounts Receivable Turnover	3.68	3.40	3.86	3.83	4.08	4.28	4.90	4.61	6.17	7.60	6.40
Inventory Turnover	1.79	1.82	1.83	1.85	1.81	1.91	1.73	1.77	1.68	1.82	1.86
Fixed Asset Turnover	8.80	8.10	7.45	8.02	7.73	7.28	7.24	9.79	10.33	10.95	11.31
Accounts Payable Turnover	7.46	7.43	5.94	8.00	7.12	5.69	5.61	7.45	6.68	6.64	6.14
Days Sales Outstanding (DSO)	99.15	107.20	94.67	95.18	89.57	85.29	74.42	79.13	59.18	48.02	57.07
Days Inventory Outstanding (DIO)	204.22	200.30	199.41	197.50	202.11	191.34	210.71	206.71	217.11	200.60	196.34
Days Payable Outstanding (DPO)	48.94	49.14	61.47	45.63	51.25	64.13	65.04	49.02	54.61	54.95	59.46
Cash Conversion Cycle (CCC)	254.44	258.37	232.61	247.05	240.43	212.51	220.08	236.82	221.67	193.66	193.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	126	120	96	89	92	75	63	57	46	26	25
Invested Capital Turnover	2.29	2.30	2.52	2.42	2.28	2.71	2.66	2.58	2.65	3.90	3.29
Increase / (Decrease) in Invested Capital	35	45	33	32	46	49	38	35	27	13	12
Enterprise Value (EV)	2,931	3,920	4,015	2,979	2,323	1,911	1,249	1,493	1,147	1,686	1,653
Market Capitalization	3,194	4,202	4,161	3,142	2,496	2,116	1,486	1,592	1,274	1,858	1,849
Book Value per Share	$7.10	$7.71	$4.64	$4.88	$5.18	$5.56	$6.61	$3.46	$3.86	$4.41	$4.95
Tangible Book Value per Share	$7.08	$7.69	$4.63	$4.86	$5.15	$5.54	$6.58	$3.43	$3.83	$4.37	$4.92
Total Capital	443	454	293	303	317	332	351	207	227	248	274
Total Debt	53	51	51	51	53	51	51	51	54	51	53
Total Long-Term Debt	51	51	51	51	51	51	51	51	51	51	51
Net Debt	-263	-282	-145	-163	-173	-206	-237	-99	-128	-171	-196
Capital Expenditures (CapEx)	1.84	1.17	0.25	1.04	1.95	8.72	5.78	5.37	5.34	0.87	1.51
Debt-free, Cash-free Net Working Capital (DFCFNWC)	100	95	73	65	67	47	39	44	34	15	15
Debt-free Net Working Capital (DFNWC)	416	429	269	279	292	305	327	194	216	237	264
Net Working Capital (NWC)	414	429	269	279	291	305	327	194	213	237	262
Net Nonoperating Expense (NNE)	5.53	5.06	5.28	6.85	6.60	6.81	6.70	7.35	8.62	11	7.14
Net Nonoperating Obligations (NNO)	-263	-282	-145	-163	-173	-206	-237	-99	-128	-171	-196
Total Depreciation and Amortization (D&A)	1.48	1.45	1.33	1.27	1.18	1.32	1.05	0.64	0.79	0.66	0.70
Debt-free, Cash-free Net Working Capital to Revenue	39.94%	42.31%	36.32%	36.79%	42.64%	34.82%	33.89%	42.90%	40.28%	19.60%	24.16%
Debt-free Net Working Capital to Revenue	166.87%	190.96%	134.77%	158.03%	186.94%	223.69%	281.23%	190.95%	253.55%	316.39%	430.22%
Net Working Capital to Revenue	166.07%	190.96%	134.77%	158.03%	185.85%	223.69%	281.23%	190.95%	250.03%	316.39%	426.20%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.45)	($0.34)	($0.40)	($0.50)	($0.51)	($0.54)	($0.51)	($0.56)	($0.63)	($0.63)	($0.51)
Adjusted Weighted Average Basic Shares Outstanding	54.92M	52.13M	52.01M	51.62M	51.01M	47.26M	48.31M	45.16M	45.07M	44.40M	44.64M
Adjusted Diluted Earnings per Share	($0.45)	($0.34)	($0.40)	($0.50)	($0.51)	($0.54)	($0.51)	($0.56)	($0.63)	($0.63)	($0.51)
Adjusted Weighted Average Diluted Shares Outstanding	54.92M	52.13M	52.01M	51.62M	51.01M	47.26M	48.31M	45.16M	45.07M	44.40M	44.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	55.33M	54.82M	52.18M	51.93M	51.42M	50.96M	50.50M	45.28M	45.05M	44.87M	44.72M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-14	-16	-19	-19	-21	-18	-18	-20	-18	-15
Normalized NOPAT Margin	-27.77%	-20.22%	-26.90%	-35.20%	-43.45%	-47.48%	-51.07%	-54.19%	-81.40%	-73.72%	-76.04%
Pre Tax Income Margin	-35.77%	-27.63%	-35.93%	-48.03%	-58.28%	-63.11%	-70.14%	-76.38%	-116.72%	-118.48%	-111.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-27.21	-18.46	-17.40	-23.88	-23.84	-23.45	-23.16	-25.20	-31.15	-5.83	-14.54
NOPAT to Interest Expense	-21.90	-14.24	-13.77	-18.23	-18.52	-18.39	-17.59	-18.59	-22.42	-4.25	-10.63
EBIT Less CapEx to Interest Expense	-29.30	-19.67	-17.61	-24.89	-25.70	-31.20	-28.84	-30.77	-37.17	-6.04	-15.58
NOPAT Less CapEx to Interest Expense	-23.99	-15.45	-13.99	-19.25	-20.38	-26.14	-23.26	-24.15	-28.45	-4.46	-11.68
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About PROCEPT BioRobotics' Financials

When does PROCEPT BioRobotics's financial year end?

According to the most recent income statement we have on file, PROCEPT BioRobotics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has PROCEPT BioRobotics' net income changed over the last 4 years?

PROCEPT BioRobotics' net income appears to be on an upward trend, with a most recent value of -$91.41 million in 2024, rising from -$53.02 million in 2020. The previous period was -$105.90 million in 2023. Check out PROCEPT BioRobotics' forecast to explore projected trends and price targets.

What is PROCEPT BioRobotics's operating income?

PROCEPT BioRobotics's total operating income in 2024 was -$96.61 million, based on the following breakdown:

Total Gross Profit: $137.10 million
Total Operating Expenses: $233.71 million

How has PROCEPT BioRobotics revenue changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' total revenue changed from $7.72 million in 2020 to $224.50 million in 2024, a change of 2,809.1%.

How much debt does PROCEPT BioRobotics have?

PROCEPT BioRobotics' total liabilities were at $131.80 million at the end of 2024, a 6.3% increase from 2023, and a 102.7% increase since 2020.

How much cash does PROCEPT BioRobotics have?

In the past 4 years, PROCEPT BioRobotics' cash and equivalents has ranged from $100.13 million in 2020 to $333.73 million in 2024, and is currently $333.73 million as of their latest financial filing in 2024.

How has PROCEPT BioRobotics' book value per share changed over the last 4 years?

Over the last 4 years, PROCEPT BioRobotics' book value per share changed from -49.93 in 2020 to 7.71 in 2024, a change of -115.4%.

Related Companies

This page (NASDAQ:PRCT) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Financials

Frequently Asked Questions About PROCEPT BioRobotics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Financials

Annual Income Statements for PROCEPT BioRobotics

Quarterly Income Statements for PROCEPT BioRobotics

Annual Cash Flow Statements for PROCEPT BioRobotics

Quarterly Cash Flow Statements for PROCEPT BioRobotics

Annual Balance Sheets for PROCEPT BioRobotics

Quarterly Balance Sheets for PROCEPT BioRobotics

Annual Metrics And Ratios for PROCEPT BioRobotics

Quarterly Metrics And Ratios for PROCEPT BioRobotics

Frequently Asked Questions About PROCEPT BioRobotics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools